- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07659795
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer (TARGET-D 203)
A Phase 2, Open-label Study of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, With and Without an Anti-EGFR Antibody, and With an Anti-EGFR Antibody and Chemotherapy, in Patients With Metastatic KRAS G12D-Mutated Colorectal Adenocarcinoma (TARGET-D 203)
This study will assess the safety and efficacy of VS-7375 alone and in combination with cetuximab or panitumumab and cetuximab plus mFOLFOX in patients with metastatic KRAS G12D - mutated Colorectal Cancer
Studieoversigt
Status
Betingelser
Intervention / Behandling
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Fase 2
Kontakter og lokationer
Studiekontakt
- Navn: Verastem Call Center
- Telefonnummer: 7812924204
- E-mail: VS-7375-203TrialSupport@verastem.com
Undersøgelse Kontakt Backup
- Navn: Bina Tejura, MD
- E-mail: VS-7375-203Medical@verastem.com
Studiesteder
-
-
New South Wales
-
Macquarie Park, New South Wales, Australien, 2109
- Rekruttering
- Macquarie University Hospital
-
Kontakt:
- Sam Ly
- Telefonnummer: +612 9812 3538
- E-mail: sam.ly@mq.edu.au
-
Kontakt:
- Jignasa Mahida
- Telefonnummer: +61 466 476 498
- E-mail: Jignasa.mahida@mq.edu.au
-
Ledende efterforsker:
- Andrew Parsonson, MBBS MMed (Clin Epi) FRACP
-
Waratah, New South Wales, Australien, 2298
- Rekruttering
- Calvary Mater Newcastle
-
Ledende efterforsker:
- Girish Mallesara, MBBS, MD, DM, FRACP
-
Kontakt:
- Kerrie Cornall
- Telefonnummer: 02 4014 3290
- E-mail: Kerrie.Cornall@health.nsw.gov.au
-
-
Queensland
-
Hyde Park, Queensland, Australien, 4812
- Rekruttering
- Icon Cancer Centre Townsville
-
Kontakt:
- Peyman Halvaeikhanekahdani
- Telefonnummer: 61747957100
- E-mail: peyman.halvaeikhanekahdani@icon.team
-
Ledende efterforsker:
- Abhishek Joshi, MBBS, MD, DM, FRACP
-
South Brisbane, Queensland, Australien, 4101
- Rekruttering
- Icon Cancer Centre South Brisbane
-
Ledende efterforsker:
- Jermaine Coward, MBBS, MRCP (UK), FRACP, PhD
-
Kontakt:
- Apryl Chelin
- Telefonnummer: 07 3737 4700
- E-mail: Apryl.chelin@icon.team
-
-
South Australia
-
Kurralta Park, South Australia, Australien, 5037
- Rekruttering
- Icon Cancer Centre Adelaide
-
Ledende efterforsker:
- Carolyn Bampton, MBBS, FRACP
-
Kontakt:
- Icon Cancer Centre Adelaide/Kurralta Park
- Telefonnummer: 08 8474 0220
- E-mail: EthicsCoordinator@icon.team
-
-
Tasmania
-
Hobart, Tasmania, Australien, 7000
- Rekruttering
- Icon Cancer Centre Hobart
-
Kontakt:
- Icon Cancer Centre Hobart
- Telefonnummer: 03 6240 2600
- E-mail: hobart.research@icon.team
-
Ledende efterforsker:
- Louise Nott, BMedSci, MBBS(Hons), FRACP
-
-
Victoria
-
Melbourne, Victoria, Australien, 3004
- Rekruttering
- Alfred Hospital
-
Kontakt:
- Ben Markman, MBBS (Hons), FRACP
- Telefonnummer: 390763129
- E-mail: ben.markman@monash.edu
-
Kontakt:
- Kate Sinn
- Telefonnummer: 390760569
- E-mail: K.Sinn@alfred.org.au
-
Ledende efterforsker:
- Ben Markman, MBBS (Hons), FRACP
-
-
-
-
Arizona
-
Scottsdale, Arizona, Forenede Stater, 85258
- Rekruttering
- HonorHealth
-
Ledende efterforsker:
- Sunil Sharma, MD
-
Kontakt:
- Sunil Sharma, MD
- Telefonnummer: 480-323-1350
- E-mail: ssharma@honorhealth.com
-
-
California
-
Los Angeles, California, Forenede Stater, 90048
- Rekruttering
- Cedars-Sinai Medical Center
-
Kontakt:
- Cedars-Sinai Trial Information
- Telefonnummer: 1-800-233-2771
- E-mail: GroupCancerTrialInformation@cshs.org
-
Ledende efterforsker:
- Jun Gong, MD
-
Los Angeles, California, Forenede Stater, 90025
- Rekruttering
- START Los Angeles
-
Kontakt:
- START Hope Team
- Telefonnummer: 424-465-1820
- E-mail: hopeteam@startresearch.com
-
Ledende efterforsker:
- Navid Hafez, M.D., MPH
-
Los Angeles, California, Forenede Stater, 90067
- Rekruttering
- Valkyrie Clinical Trials (contact for more locations)
-
Ledende efterforsker:
- David Berz, MD, PhD, MPH
-
Kontakt:
- Trenis Palmer, PhD
- Telefonnummer: 912-398-3205
- E-mail: trenis.palmer@vctcare.com
-
-
Florida
-
Coral Springs, Florida, Forenede Stater, 33065
- Rekruttering
- BRCR - Coral Springs
-
Ledende efterforsker:
- Sumit Sawhney, MD
-
Kontakt:
- Sumit Sawhney, MD
- Telefonnummer: 561-447-0614
- E-mail: ssawhney.md@brcrglobal.com
-
Tamarac, Florida, Forenede Stater, 33321
- Rekruttering
- BRCR - Tamarac
-
Ledende efterforsker:
- Andrew Schneider, MD
-
Kontakt:
- Diana Casas
- Telefonnummer: 561-447-0614
- E-mail: dianac@brcrglobal.com
-
Tampa, Florida, Forenede Stater, 33612
- Rekruttering
- Moffitt Cancer Center
-
Ledende efterforsker:
- Tiago Biachi de Castria, MD, PhD
-
Kontakt:
- Cheyenne Schneider
- Telefonnummer: 813-745-3691
- E-mail: Cheyenne.Schneider@moffitt.org
-
-
Indiana
-
Indianapolis, Indiana, Forenede Stater, 46202
- Rekruttering
- Indiana University, Simon Comprehensive Cancer Center
-
Kontakt:
- Yvonne LaFary
- Telefonnummer: 317-278-5613
- E-mail: ylafary@iu.edu
-
Ledende efterforsker:
- Anita Turk, M.D.
-
-
Michigan
-
Grand Rapids, Michigan, Forenede Stater, 49546
- Rekruttering
- START Midwest
-
Kontakt:
- START Hope Team
- Telefonnummer: 616-954-5554
- E-mail: hopeteam@startresearch.com
-
Ledende efterforsker:
- Sreenivasa R Chandana, M.D., Ph.D.
-
-
Missouri
-
St Louis, Missouri, Forenede Stater, 63110
- Rekruttering
- Washington University
-
Ledende efterforsker:
- Kian-Huat Lim, M.D., Ph.D.
-
Kontakt:
- Caroline Bumb
- Telefonnummer: 314-747-4000
- E-mail: cbumb@wustl.edu
-
-
New Jersey
-
East Brunswick, New Jersey, Forenede Stater, 08816
- Rekruttering
- START New Jersey
-
Kontakt:
- START Hope Team
- Telefonnummer: 732-426-4750
- E-mail: hopeteam@startresearch.com
-
Ledende efterforsker:
- Bruno S Fang, M.D.
-
-
New York
-
New York, New York, Forenede Stater, 10016
- Rekruttering
- Perlmutter Cancer Center at NYU Langone Health (contact for more locations)
-
Kontakt:
- Rafael Winograd, MD, PhD
- Telefonnummer: 646-501-7802
- E-mail: CancerTrials@nyulangone.org
-
Ledende efterforsker:
- Rafael Winograd, MD, PhD
-
-
North Carolina
-
Chapel Hill, North Carolina, Forenede Stater, 27514
- Rekruttering
- University of North Carolina
-
Kontakt:
- Catherine Griffin
- Telefonnummer: 919-966-4432
- E-mail: catherine_griffin@med.unc.edu
-
Ledende efterforsker:
- Michael Iglesia, MD, PhD
-
-
Ohio
-
Cleveland, Ohio, Forenede Stater, 44106
- Rekruttering
- Case Western, University Hospitals Cleveland Medical Center
-
Ledende efterforsker:
- Amit Mahipal, MD
-
Kontakt:
- Amit Mahipal, MD
- Telefonnummer: (216)844-6031
- E-mail: Amit.Mahipal@UHhospitals.org
-
-
Tennessee
-
Nashville, Tennessee, Forenede Stater, 37203
- Rekruttering
- Sarah Cannon Research Institute Oncology Partners
-
Ledende efterforsker:
- Meredith Pelster, MD
-
Kontakt:
- ASK SARAH
- Telefonnummer: 877-691-7274
- E-mail: askSARAH@scresearch.net
-
-
Texas
-
Fort Worth, Texas, Forenede Stater, 76104
- Rekruttering
- START Dallas Fort Worth
-
Kontakt:
- START Hope Team
- Telefonnummer: 682-350-3010
- E-mail: hopeteam@startresearch.com
-
Ledende efterforsker:
- Salwan Al Mutar, M.D., M.Sc.
-
Houston, Texas, Forenede Stater, 77030
- Rekruttering
- The University of Texas MD Anderson Cancer Center
-
Ledende efterforsker:
- Christine Parseghian, MD
-
Kontakt:
- MD Anderson Cancer Center, GI Medical Oncology Dept
- Telefonnummer: 855-982-0789
- E-mail: GIClinicalTrials@mdanderson.org
-
-
Utah
-
Salt Lake City, Utah, Forenede Stater, 84112
- Rekruttering
- Huntsman Cancer Institute - University of Utah
-
Ledende efterforsker:
- Christopher Nevala-Plagemann, MD
-
Kontakt:
- Susan Sharry
- Telefonnummer: 801-585-3453
- E-mail: susan.sharry@hci.utah.edu
-
West Valley City, Utah, Forenede Stater, 84119
- Rekruttering
- START Mountain Region
-
Kontakt:
- START Hope Team
- Telefonnummer: 801-907-4750
- E-mail: hopeteam@startresearch.com
-
Ledende efterforsker:
- José M Pacheco, M.D.
-
-
Virginia
-
Charlottesville, Virginia, Forenede Stater, 22908
- Rekruttering
- UVA Comprehensive Cancer Center
-
Ledende efterforsker:
- Matthew Reilley, MD
-
Kontakt:
- Clinical Trials Navigator
- Telefonnummer: 434-982-0539
- E-mail: UVACANCERTRIALS@uvahealth.org
-
Fairfax, Virginia, Forenede Stater, 22031
- Rekruttering
- Virginia Cancer Specialists
-
Kontakt:
- VCS Research Referrals
- Telefonnummer: 703-636-1473
- E-mail: vcsresearchreferrals@usoncology.com
-
-
Washington
-
Seattle, Washington, Forenede Stater, 98101
- Rekruttering
- Virginia Mason Medical Center
-
Kontakt:
- Cancer Research Team
- Telefonnummer: 206-287-6270
- E-mail: crp@benaroyaresearch.org
-
Ledende efterforsker:
- Jessica Lee, DO
-
-
Wisconsin
-
Madison, Wisconsin, Forenede Stater, 53792
- Rekruttering
- University of Wisconsin
-
Ledende efterforsker:
- Dustin Deming, MD
-
Kontakt:
- UW Cancer Connect
- Telefonnummer: 800-622-8922
- E-mail: cancerconnect@uwhealth.org
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
-
Histopathology confirmed metastatic CRC
-
Measurable disease per RECIST 1.1
-
Local testing confirmed KRAS G12D mutation (tissue required for confirmatory central testing)
-
ECOG PS=0 or 1
2L+ patients:
-
Must have received at least 1 standard chemotherapy for metastatic colorectal adenocarcinoma
-
Have documented disease progression during or following their most recent prior line of therapy
-
Have either stable disease, partial response (PR), or complete response (CR) by RECIST v1.1 as the best overall response (BOR) during at least 1 prior systemic therapy.
1L patients:
-
Treatment-naïve or received no more than 1 cycle of standard systemic therapy for metastatic disease.
Exclusion Criteria:
- Have any other documented co-existing common RAS mutation(s)
- Prior anti-cancer Tx within 4 weeks or drug-specific timeline within first treatment dose, whichever shorter
- Major surgery within 4 weeks of first treatment dose
- Radiation therapy (RT) within 1 week of first treatment dose
- Receipt of prior direct RAS inhibitor
- Receipt of more than 1 investigational therapy
- Untreated or symptomatic CNS metastasis
- Receipt of strong CYP3A4 inhibitor/inducer or CYP3A4 sensitive substrates with narrow therapeutic index within 14 days or drug-specific timeline within first treatment dose, whichever is shorter
- Receipt of PPI or H2 blocker within 5 days
- Inability to swallow oral medication
- Other protocol-defined inclusion/exclusion criteria may apply
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Crossover opgave
- Maskning: Enkelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: VS-7375 with chosen regimen in 2L+ CRC
|
Taken by mouth Intravenous infusion Intravenous infusion |
|
Eksperimentel: VS-7375 + cetuximab and mFOLFOX in 1L CRC
|
Intravenous infusion |
|
Eksperimentel: VS-7375 Monotherapy or Preferred Combination in 2L+ CRC
Participants randomized to a treatment in 2:1 ratio |
Taken by mouth Intravenous infusion Intravenous infusion |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Confirmed ORR by blinded independent central review (BICR) per RESIST v1.1 - 2L CRC only
Tidsramme: 6 months
|
Overall Response Rate per RECIST version 1.1, per blinded independent central review (BICR) |
6 months
|
|
To characterize the safety and tolerability of VS-7375 monotherapy or in combination with cetuximab or panitumumab, administered on a daily oral schedule in participants with KRAS G12D-mutated 2L+ CRC
Tidsramme: 6 months
|
Proportion/number of participants with AEs, TEAEs, TRAEs, SAEs, and dose interruptions/reductions and discontinuations |
6 months
|
|
To characterize the safety and tolerability of VS-7375 in combination with cetuximab + mFOLFOX, administered on a daily oral schedule in participants with KRAS G12D-mutated 1L CRC
Tidsramme: 6 months
|
Proportion/number of participants with AEs, TEAEs, TRAEs, SAEs, and dose interruptions/reductions and discontinuations |
6 months
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Plasma Pharmacokinetics (PK) of VS-7375 and relevant metabolites, Cmax
Tidsramme: 20 weeks
|
Maximum concentration (Cmax) |
20 weeks
|
|
Plasma Pharmacokinetics (PK) of VS-7375 and relevant metabolites, AUC
Tidsramme: 20 weeks
|
Area under plasma Concentration (AUC) 0 to t |
20 weeks
|
|
To evaluate Pharmacodynamics (PD) and other relevant blood tumor markers specific to tumor type
Tidsramme: Up to 2.5 years
|
CA19-9, CEA, CA-125 |
Up to 2.5 years
|
|
Time to next therapy
Tidsramme: 24 months
|
To assess the interval between initiation of study treatment and initiation of subsequent treatment |
24 months
|
|
Confirmed ORR per RECIST v1.1 assessed by BICR (primary) and Investigator (secondary) assessments
Tidsramme: 24 months
|
To evaluate additional efficacy parameters of VS-7375 monotherapy and VS-7375 in combination with cetuximab or panitumumab or cetuximab + mFOLFOX, administered on a daily oral schedule in participants with KRAS G12D-mutated CRC |
24 months
|
|
To assess the health-related quality of life and disease based on European Organization for Research and Treatment of Cancer (EORTC) Quality of life Questionnaire Core module C30 (QLQ-C30)
Tidsramme: 24 months
|
The EORTC QLQ-C30 is a validated questionnaire to assess the quality of life of colorectal cancer patients |
24 months
|
Andre resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Imaging of tumor metabolism changes in 2L monotherapy patients
Tidsramme: 24 months
|
To assess tumor metabolism dynamics on FDG-PET/CT |
24 months
|
Samarbejdspartnere og efterforskere
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Neoplasmer efter sted
- Neoplasmer
- Tarmsygdomme
- Gastrointestinale neoplasmer
- Neoplasmer i fordøjelsessystemet
- Sygdomme i fordøjelsessystemet
- Gastrointestinale sygdomme
- Intestinale neoplasmer
- Endetarmssygdomme
- Tyktarmssygdomme
- Kolorektale neoplasmer
- Aminosyrer, peptider og proteiner
- Proteiner
- Antistoffer, monoklonal, humaniseret
- Antistoffer, monoklonal
- Antistoffer
- Immunoglobuliner
- Immunoproteiner
- Blodproteiner
- Serum globuliner
- Globuliner
- Panitumumab
- Cetuximab
Andre undersøgelses-id-numre
- VS-7375-203
- 2026-526473-42-00 (Ctis)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .